Abbott has introduced its new DRG Invisible Trial System, following approval from the US Food and Drug Administration (FDA) and grant of the European CE-Mark, to help in chronic pain management.
Designed as a non-opioid treatment option, the new device delivers the company’s dorsal root ganglion (DRG) stimulation and enables patients to trial the therapy before opting for a device implant.
DRG therapy alleviates neuropathic pain conditions by transmitting electrical pulses over the DRG to block pain signals.
Findings from the clinical research showed that DRG therapy can deliver better pain relief compared to conventional spinal cord stimulation (SCS) therapy in patients with persistent neuropathic focal pain conditions.
Patients experiencing adequate pain relief with the therapy can have an Abbott Proclaim DRG system implanted for their pain management.
Abbott neuromodulation medical director Allen Burton said: “With Abbott’s pioneering work to provide new options to treat different types of chronic pain, the intuitive DRG Invisible Trial System gives pain sufferers new hope.
“By enabling a temporary trial, people can test the treatment before receiving a permanent implant. If they experience meaningful pain relief, they can choose to move forward with our DRG therapy and find long-term pain relief-helping them live a fuller, healthier life again without relying on opioids.”
The DRG Invisible Trial System enables a minimally invasive assessment period, for which thin wires are placed in the spinal column near the DRG during an outpatient procedure.
In addition, a small external battery is placed under clothes in order to hide it from the public.
The patient can use an Apple iPod touch to manage their pain relief for approximately one week. The user can change the stimulation settings within prescribed limits to assess the effect of DRG therapy on their chronic pain symptoms.